BRAF (B-raf proto-oncogene)

P4, N=90, Recruiting, NYU Langone Health | Not yet recruiting --> Recruiting

P4, N=0, Withdrawn, SRH Wald-Klinikum Gera GmbH | N=101 --> 0 | Not yet recruiting --> Withdrawn

P3, N=360, Recruiting, Immatics US, Inc. | N=96 --> 360

P1, N=387, Not yet recruiting, Shanghai Henlius Biotech

P=N/A, N=48, Recruiting, University of Arizona | Not yet recruiting --> Recruiting

Understanding these dynamics is essential for developing targeted public health strategies that address the unique challenges faced by this population, balancing their cultural heritage with the realities of modern American life. Further analysis and wider scope studies are necessary to explore the implications of these findings on health outcomes.

We report a 69-year-old man with resectable stage IIB right upper lobe lung adenocarcinoma who received neoadjuvant pembrolizumab, carboplatin, and pemetrexed followed by robotic-assisted lobectomy. He received adjuvant pembrolizumab and daratumumab-CyBorD with partial hematologic response. This case highlighted that amyloid can unexpectedly be a second diagnosis after post-neoadjuvant lung resections and that proteomic subtyping is essential for prompt haematologic staging and treatment.

These results indicate that rare BRAF mutations can modify BRAF kinase activity including a subset of mutations outside but close to codon 600. Molecular approaches able to detect rare BRAF mutations could identify additional melanoma cases eligible for therapies with BRAF/MEK inhibitors.

This report adds an insight into the involvement of genetic events in histological transformation in EGFR-mutated lung cancer.

Beyond oncology, MEK pathway modulation is under investigation in fibrotic, inflammatory, and developmental disorders, although clinical validation remains at an early stage. Building on more than a decade of use in BRAFV600 (ie, Val600)-mutant melanoma, MEK inhibitors continue to be refined through biomarker-guided combination strategies and exploration in additional cancers and non-oncological diseases.

We have identified a small molecule produced by a marine sponge as being able to inhibit PTCH1 efflux activity and increase the efficacy of vemurafenib treatment on BRAF-mutated melanoma cells in vitro and in vivo in mice. We found that inhibiting PTCH1 drug efflux activity significantly increased the cytotoxic effect of chemotherapies such as doxorubicin and docetaxel in three TNBC cell lines. Overall, our findings suggest that PTCH1 plays a role in the resistance of TNBC cells to chemotherapy, and that using a PTCH1 efflux inhibitor during neoadjuvant or adjuvant therapy could enhance the efficacy of treatment against PTCH1-expressing TNBC, while preventing treatment resistance, relapse, and metastasis formation.

Serial pCGP can inform treatment decisions in patients with NSCLC. In those with EGFR-mutant disease, pCGP at progression identifies actionable drivers of therapy resistance, enabling therapeutic intervention.